预约演示
更新于：2025-06-14
Agatolimod
阿托莫德
更新于：2025-06-14
概要
基本信息
权益机构- |
最高研发阶段临床前 |
首次获批日期- |
最高研发阶段(中国)终止 |
特殊审评- |
登录后查看时间轴
结构/序列
使用我们的RNA技术数据为新药研发加速。
登录
或
Sequence Code 29253626
来源: *****
关联
46
项与 阿托莫德 相关的临床试验ChiCTR2000036023
Combined treatment of thermal ablation and CpG 7909/Pembrolizumab for colorectal liver metastases
开始日期2020-10-01 |
申办/合作机构- |
JPRN-jRCTs061180034
A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer - A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer
开始日期2016-05-17 |
申办/合作机构- |
NCT01164514
A Randomized, Partial-Blinded, Placebo-Controlled, Phase I Safety and Immunogenicity Study in Healthy Subjects of Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram Negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant
The purpose of this study is to test the safety of an experimental vaccine against sepsis (infection of the blood) alone and with an experimental adjuvant (a substance that may improve vaccine effectiveness). This study will also find out how well antibodies are made after receiving vaccine alone or vaccine combined with adjuvant. Participants will include up to 34 healthy volunteers between the ages 18-50 years. Participants will be randomly assigned to 1 of 4 groups to receive vaccine alone, vaccine with adjuvant (2 different dosages) or placebo (inactive substance). Participants will receive 3 vaccinations at different times during the study (Day 0, Day 29 and Day 59). Study procedures will include blood samples, urine samples, electrocardiogram (measures heart activity) and a completion of a memory aid to document side effects. Participation will involve 16 clinic visits and 3 follow-up telephone calls over 12 months.
开始日期2011-11-01 |
100 项与 阿托莫德 相关的临床结果
登录后查看更多信息
100 项与 阿托莫德 相关的转化医学
登录后查看更多信息
100 项与 阿托莫德 相关的专利（医药）
登录后查看更多信息
1,297
项与 阿托莫德 相关的文献（医药）2025-12-31·Human Vaccines & Immunotherapeutics
Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study
Article
作者: Hapsari, Rebriarina ; Farhanah, Nur ; Pramudo, Setyo Gundi ; Sekartini, Rini ; Wirahmadi, Angga ; Sari, Rini Mulia ; Maria, Suzy ; Mahati, Endang ; Yeremia, Glenn Fernandez ; Mulyono, Mulyono ; Anantyo, Dimas Tri ; Puspita, Mita ; Nency, Yetty Movieta ; Maharani, Nani ; Setyaningsih, Lilis
Indonesian vaccine producer (PT BIOFARMA), conducted a study to assess the safety and immunogenicity of a new COVID-19 vaccine candidate. This vaccine is based on a recombinant subunit protein platform, with the SARS-CoV-2 receptor-binding domain (RBD) as its target antigen. The study compared the candidate's safety and immunogenicity to the control group vaccine, the Sinovac vaccine, 28 days after administration. This was an observer-blinded and randomized Phase 1 trial which recruited 175 subjects. The subject received 0.5 ml of vaccine in two doses. The subjects were split into five treatment groups, consisting of different combinations of doses between RBD and CpG. The safety of this vaccine was evaluated within 7 days after the first dose and for 6 months after the second dose, while the immunogenicity was evaluated on days 14 and 28 after the second dose. The overall incidence of AEs was 54.86% from the beginning of the vaccination to 28 days after each injection. Most AEs were local pain and had no serious AEs. The study revealed a significant rise in the Geometric Mean Titer (GMT) of IgG antibodies in every group, indicating a strong immune response. The phase I data demonstrated that the new vaccine candidate showed promising results in safety and immunogenicity.
2025-06-01·Journal of Esthetic and Restorative Dentistry
Comparative Analysis Between Strip and Gels Indicated for at Home Bleaching: Analysis of Color Alteration, Roughness and Microhardness of Dental Enamel
Article
作者: Ferreira, M. C. B. ; Briso, A. L. F. ; Esteves, L. M. B. ; Fagundes, T. C. ; Catelan, A. ; Cintra, L. T. A. ; Aidar, K. M. S. ; Goto, J.
ABSTRACT:
Purpose:
To compare the color alteration, surface roughness and microhardness and cross‐sectional microhardness of bovine enamel treated with at‐home whitening strips and gels.
Materials and Methods:
Sixty‐six pigmented specimens (n = 11) were allocated to six groups: C—cotton wool moistened with distilled water for 1 h; SDS—sodium dithionite strip, for 1 h; HPS—6.5% hydrogen peroxide strip, for 1 h; CPS—20% carbamide peroxide strip, for 1 h; HPG—7.5% hydrogen peroxide gel, for 1 h; CPG—10% carbamide peroxide gel, for 4 h. The treatments lasted 10 days, calculating the ∆E, ∆E00, and ∆WID at baseline, 5 and 10 days, and 14 days after completion. Additional 66 polished discs (n = 11) were used to analyze the surface roughness and microhardness of enamel before and after bleaching, cross‐sectional microhardness and integrated mineral loss (ΔZ; %Vol × μm). Data were subjected to statistical analysis by two‐way Anova RM and Tukey post‐test (α = 0.05).
Results:
In ∆E and ∆WID analysis, greater values were obtained in CPG (p < 0.001), followed by HPG and HPS (p = 0.271). SDS and CPS (p < 0.001) exceeded only C (p < 0.001). In ∆E00, at completion of treatments, the results were similar; however, HPG = HPS = CPS (p = 0.237). There was an increase in roughness and decrease in surface microhardness in all bleaching groups (p < 0.005). Concerning the cross‐sectional microhardness, the treatments were equal to C at 150 μm, the last depth analyzed. For ΔZ, the values of SDS, CPS, HPG, and CPG groups showed similar mineral loss (p > 0.001), and the lowest value was exhibited in the Control group, followed by HPS group (p < 0.001).
Conclusion:
Although the strips were aesthetically effective, the CPG and HPG groups presented highest values in the ∆E00 and ∆WID analysis. However, all treatments influenced the enamel surface, increasing roughness and decreasing surface and transverse microhardness.
Clinical Relevance:
The whitening gels promoted greater chromatic changes, but all treatments affected the enamel surface, increasing roughness and decreasing surface and transverse microhardness.
2025-05-30·JOURNAL OF NANOBIOTECHNOLOGY
Immunogenicity and cellular response of a herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice.
Article
作者: Zhang, Jun ; Xia, Ningshao ; Zheng, Qingbing ; Wang, Hong ; Yu, Hai ; Liu, Hongjing ; Chen, Tingting ; Li, Shaowei ; Xiong, Yueting ; Gu, Ying ; Cheng, Tong ; Zhang, Sibo ; Zhang, Yiwen ; Xue, Wenhui ; Chen, Lin ; Zeng, Yarong ; Cui, Lingyan ; Zhou, Lizhi ; Li, Tingting ; Zhang, Yuyun
Herpes zoster (HZ), commonly known as shingles, arises from the reactivation of the latent varicella-zoster virus (VZV) when VZV-specific cellular immunity declines below a critical threshold necessary for viral suppression. The current leading vaccine, Shingrix, which incorporates the adjuvant AS01B with glycoprotein E (gE), has significantly contributed to HZ prevention but raises concerns regarding safety and accessibility. Addressing the need for safer and more accessible HZ vaccinations, we developed a vaccine comprising a fusion protein of glycoprotein E and I (gEgI), connected via a linker, targeting abundant B cell and CD4 T cell epitopes. Our study assessed the immunogenicity of the gE alone and the gEgI fusion protein in adult mice, revealing that gEgI prompts a more potent and comprehensive T cell response compared to gE alone. Furthermore, we introduced a composite adjuvant, an emulsion-type adjuvant combined with CpG1018 (XUA09C), which was shown to enhance both humoral and cellular immune responses beyond the capabilities of XUA09 with CpG alone. Comparative analyses demonstrated that the XUA09C-adjuvanted gEgI vaccine induces comparable antibody responses and significantly superior T cell responses relative to Shingrix in both adult, VZV-primed, and aged mice. Single-cell RNA sequencing highlighted that gEgI/XUA09C more effectively promotes early immune activation, B and T cell proliferation, and memory T cell augmentation compared to Shingrix. These findings position the XUA09C-adjuvanted gEgI as a promising candidate for further development in HZ vaccine strategies, potentially better serving the needs of the immunocompromised population.
32
项与 阿托莫德 相关的新闻（医药）2025-06-12
Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress will feature the latest advances in the treatment of diffuse large B-cell lymphoma (DLBCL), immune thrombocytopenia (ITP), myelofibrosis, paroxysmal nocturnal haemoglobinuria (PNH), and primary hemophagocytic lymphohistiocytosis (pHLH).
An extensive programme of poster presentations will showcase Sobi’s commitment to helping patients with rare diseases by advancing treatment options. In addition, Sobi will host several scientific symposiums at the congress including: 1.Advancing Therapeutic Knowledge in Paroxysmal Nocturnal Haemoglobinuria: Reshaping disease management to unlock new norms, Thursday, 12 June, 10:00am - 11:30am CEST, at Amber Hall 3 & 4. 2. Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP), Saturday 14 June, 8.00 am - 9.30 am CEST, at Amber Hall 7 & 8. 3. Dissecting Treatment Sequencing in relapsed/refractory DLBCL, from laboratory to real life. Saturday, 14 June, 8:00 am – 9:30 am, CEST at Coral Hall 1. “The breadth of data that we share at this year’s EHA congress demonstrates Sobi’s comprehensive approach to addressing rare conditions in haematology. We are proud to contribute to advancing the science in several indications from early clinical phases in diffuse large B-cell lymphoma to clinical and real-world evidence in myelofibrosis, primary hemophagocytic lymphohistiocytosis, immune thrombocytopenia and paroxysmal nocturnal haemoglobinuria,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.
Key data to be presented at EHA 2025
DLBCL
PS1911: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large BCell Lymphoma (DLBCL) Presenting Author: Juan Pablo Alderuccio
Poster presentation
Session title: Poster Session 2Session date: Saturday, 14 June
Session time: 18:30-19:30 CEST
Location: Poster Hall
PS1957: Updated Safety Run-in Results from LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine with Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL
Presenting Author: Carmelo Carlo-Stella
Immune Thrombocytopenia (ITP)
PF1236: Platelet Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia Who Switched from Eltrombopag or Romiplostim: the REAL-AVA 2.0 Real-World Study
Presenting Author: Shruti Chaturvedi
Poster presentation
Session title: Poster Session 1Session date: Friday, 13 June
Session time: 18:30 - 19:30 CEST
Location: Poster Hall
PF1239: Durability of Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia: The REAL-AVA 2.0 Real-World Study
Presenting Author: Srikanth Nagalla
PF1251: Clinically Meaningful Response to Avatrombopag: A Phase 3B Trial for Treatment of Children with ITP
Presenting Author: Rachael F. Grace
PS2231: Effectiveness and safety of avatrombopag for the treatment of adults with newly diagnosed, persistent, or chronic immune thrombocytopenia: Interim results from the phase 4 ADOPT study
Presenting Author: Waleed Ghanima
Poster presentation
Session title: Poster Session 2Session date: Saturday, 14 June
Session time: 18:30 - 19:30 CEST
Location: Poster Hall
PS2234: Efficacy and safety of avatrombopag for the treatment of pediatric immune thrombocytopenia in the open-label extension of a phase 3, randomized, double-blind, placebo-controlled trial
Presenting Author: Rachael F. Grace
PS2239: Real-World Treatment Patterns & Clinical Outcomes in Thrombopoietin Receptor Agonist Naive Patients with Immune Thrombocytopenia Treated with Avatrombopag: Interim Results from the REAL-AVA 3.0 Study
Presenting Author: Sandhya Panch
PS2242: Effectiveness and safety of avatrombopag for treatment of immune thrombocytopenia in older patients and those with comorbidities or prior TPO-RA exposure: Interim results from the phase 4 ADOPT study
Presenting Author: María Eva Mingot-Castellano
PS2244: Response to Avatrombopag Among Patients with Chronic and Persistent Primary Immune Thrombocytopenia: the REAL-AVA 2.0 Real-World Study
Presenting Author: M Y Levy
PS2250: Evaluation of Efficacy and Safety of Avatrombopag in Children with Immune Thrombocytopenia based on Disease Duration: Results from the Avatrombopag Phase 3-b Pediatric Trial
Presenting Author: Rachael F. Grace
PB3676: Baseline Correlates with Durability of Avatrombopag Response: A Phase 3B Trial for Treatment of Children with ITP
Publication Only
Published on May 14 at 15:30 CEST
PB3684: Consistent Response to Avatrombopag across Various Baseline Characteristics: Results from the Phase 3-b Trial for the Treatment of Children with Immune Thrombocytopenia
Myelofibrosis
PF849: Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in real-world clinical settings
Presenting Author: Michael Marrone
Poster presentation
Session title: Poster Session 1Session date: Friday, 13 June
Session time: 18:30 - 19:30 CEST
Location: Poster Hall
PF1242: Efficacy of pacritinib vs momelotinib in patients with thrombocytopenic MF: a matched adjusted indicated treatment comparison
Presenting Author: Koo Wilson
PF1306: Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial
Presenting Author: Abiola Oladapo
PS1827: Real-world effectiveness of pacritinib in patients with myelofibrosis who have concurrent thrombocytopenia and anemia
Presenting Author: Raajit Rampal
Poster presentation
Session title: Poster Session 2
Session date: Saturday, 14 June
Session time: 18:30-19:30 CEST
Location: Poster Hall
PS1842: Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x109/L at PAC initiation: Interim results from the MY-PAC Study
Presenting Author: Doug Tremblay
PS2295: Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database
Presenting Author: Lucia Marasova
PB3079: Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database
Publication Only
Published on May 14 at 15:30 CEST
Paroxysmal Nocturnal Hemoglobinuria
PF672: Early response in complement inhibitor naïve patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan in the Phase 3 PRINCE trial
Presenting Author: Austin Kulasekararaj
Poster presentation
Session title: Poster Session 1Session date: Friday, 13 June
Session time: 18:30 - 19:30 CEST
Location: Poster Hall
PF676: Interim analysis of the ongoing COMPLETE study on the real-world effectiveness of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Presenting Author: Regis Peffault de Latour
PS1662: A benefit assessment of pegcetacoplan dose increase in the Phase 3 PEGASUS trial of PNH patients with difficult-to-control disease
Presenting Author: Morag Griffin
Poster presentation
Session title: Poster Session 2Session date: Saturday, 14 June
Session time: 18:30 - 19:30 CEST
Location: Poster Hall
PS1665: Benefit of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria irrespective of baseline transfusion status
Presenting Author: Britta Höchsmann
Primary Hemophagocytic Lymphohistiocytosis (pHLH)
PF1036: Emapalumab in patients with primary hemophagocytic lymphohistiocytosis: Efficacy and safety outcomes from a multinational, open-label, single-arm study
Presenting Author: Franco Locatelli
Poster presentation
Session title: Poster Session 1Session date: Friday, 13 June
Session time: 18:30 - 19:30 CEST
Location: Poster Hall
About pegcetacoplan in rare diseases Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for rare diseases across haematology and nephrology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as EMPAVELI®/Aspaveli® in the United States, European Union, and other countries globally
About Doptelet® (avatrombopag) Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
About Zynlonta® (loncastuximab tesirine)Zynlonta® (loncastuximab tesirine) is a CD19-directed antibody drug conjugate (ADC). Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.
About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.
临床3期免疫疗法临床结果上市批准临床1期
2025-05-28
Net sales amounted to 0 (0) TSEK The operating result for the period was -1 254 (-1) TSEK The net result was -1 311 (-5) TSEK corresponding to earnings per share of -0,01 (-0.00) SEK Cash flow from operating activities amounted to -738 (-64) TSEK Cash and cash equivalents amounted to 4 768 (10 947) TSEK
On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024. Due to the reasons to believe that the company’s equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22. The balance sheet for liquidation purpose prepared and reviewed by the company’s auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting.
During the first quarter, the focus has continued to be on trying to commercialize the three projects Nanoimod, Nanodotax and NOV 202. Furthermore, the work to reduce the company’s costs has continued.
In beginning of April, we finally concluded, after extensive attempts, that Lidds will not succeed with the investments on which we have concentrated the company’s resources on and therefore we did not see any opportunity to capitalize the company for further clinical studies. As a result, the board of directors decided to terminate further development of these project areas. The work will now be fully focused on utilizing the values that the company owns in the form of the NanoZolid technology platform and its patents, the subsidiary Noviga with the drug candidate NOV 202 and its patents. In addition, we will investigate the interest for the company’s listing on First North and any values for the accumulated loss carry forwards that have arisen.
Mats Wiking CEO and CFO
The interim report is available on the company’s website https://liddspharma.com/en/investors/financial-reports/.
For additional information, please contact
Mats Wiking, CEO and CFO Phone: +46 (0)70 620 04 00 E-mail: mats.wiking@liddspharma.com
LIDDS’ Certified Adviser is Redeye AB
LIDDS in brief:
LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.
财报
2025-05-28
The year in the headings has been corrected to 2025.
First quarter 2025 (the Group) ·Net sales amounted to 0 (0) TSEK ·The operating result for the period was -1 254 (-1) TSEK ·The net result was -1 311 (-5) TSEK corresponding to earnings per share of -0,01 (-0.00) SEK ·Cash flow from operating activities amounted to -738 (-64) TSEK ·Cash and cash equivalents amounted to 4 768 (10 947) TSEK Significant events after the reporting period (during April) ·On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. ·Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024. ·Due to the reasons to believe that the company’s equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22. ·The balance sheet for liquidation purpose prepared and reviewed by the company’s auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting.
CEO statement
During the first quarter, the focus has continued to be on trying to commercialize the three projects Nanoimod, Nanodotax and NOV 202. Furthermore, the work to reduce the company's costs has continued. In beginning of April, we finally concluded, after extensive attempts, that Lidds will not succeed with the investments on which we have concentrated the company's resources on and therefore we did not see any opportunity to capitalize the company for further clinical studies. As a result, the board of directors decided to terminate further development of these project areas. The work will now be fully focused on utilizing the values that the company owns in the form of the NanoZolid technology platform and its patents, the subsidiary Noviga with the drug candidate NOV 202 and its patents. In addition, we will investigate the interest for the company's listing on First North and any values for the accumulated loss carry forwards that have arisen.
Mats Wiking CEO and CFO
The interim report is available on the company’s website https://liddspharma.com/sv/investerare/finansiella-rapporter/
For additional information, please contact
Mats Wiking, CEO and CFO Phone: +46 (0)70 620 04 00 E-mail: mats.wiking@liddspharma.com
LIDDS’ Certified Adviser is Redeye AB
LIDDS in brief:
LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.
Attachments
LIDDS Interim Report Q1 2025
财报
100 项与 阿托莫德 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期非小细胞肺癌 | 临床3期 | 美国 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 中国 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 澳大利亚 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 奥地利 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 比利时 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 巴西 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 加拿大 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 塞浦路斯 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 捷克 | 2005-11-01 | |
| 晚期非小细胞肺癌 | 临床3期 | 法国 | 2005-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1/2期 | 23 | (Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909) | 餘艱鏇餘鹹襯窪願觸製 = 窪築構簾願蓋遞衊構網 範淵鬱簾顧糧憲繭窪獵 (網網顧築齋鹹襯鏇網製, 蓋襯衊壓築獵夢衊觸糧 ~ 廠憲願獵鹽鬱積簾壓顧) 更多 | - | 2022-04-07 | ||
(Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51) | 餘艱鏇餘鹹襯窪願觸製 = 醖願夢淵鹽築餘襯鹽餘 範淵鬱簾顧糧憲繭窪獵 (網網顧築齋鹹襯鏇網製, 鏇襯築蓋齋鏇願鹽網淵 ~ 觸齋夢鹽網襯觸構醖構) 更多 | ||||||
N/A | - | CpG/OX40/cGAMP | 蓋簾鏇鏇積網廠鹹積鹹(糧夢艱鑰獵壓醖餘繭糧) = 築夢鏇積簾齋蓋膚襯顧 鹽構窪餘窪糧糧製繭簾 (獵襯廠願積鹹廠觸淵鑰 ) | - | 2021-09-25 | ||
临床1期 | 14 | 糧製艱襯鑰簾鑰鹹壓餘 = 壓窪遞選窪觸觸範蓋衊 壓製襯鑰廠夢艱鑰遞鹹 (簾憲齋齋築願齋鏇夢繭, 鑰鬱糧衊築艱構鬱餘壓 ~ 蓋鏇簾窪糧願鏇築網衊) 更多 | - | 2021-07-15 | |||
临床2期 | 黑色素瘤 辅助 | - | Saline | 網壓夢壓製積繭簾壓築(醖鹽醖淵選淵窪艱獵齋) = 築遞蓋積齋網夢範獵積 選鹹醖繭齋鬱糧餘選製 (鏇憲範窪鹹鏇範醖獵製, 21 ~ 71) | 积极 | 2017-07-01 | |
临床2期 | 30 | Local radiotherapy+PF-3512676 | 膚鏇憲築築觸繭製餘艱 = 遞糧糧範蓋製淵淵憲鹹 糧顧繭衊遞選鬱艱襯膚 (窪簾鬱夢鑰膚繭夢積窪, 齋鑰鹽遞淵鹹遞夢鏇鹹 ~ 獵願積繭齋製夢襯夢淵) 更多 | - | 2017-03-14 | ||
临床2期 | 6 | 鑰廠餘選顧遞夢衊簾淵(築積壓膚夢廠鹹願鏇積) = 製齋衊齋夢壓蓋築醖構 積築鬱壓壓淵製簾築鹹 (獵餘鹹構願齋鹽簾鏇夢, 遞繭鹽遞遞顧遞蓋選網 ~ 壓鏇鹽淵膚壓夢艱艱艱) 更多 | - | 2016-01-14 | |||
临床2期 | 黑色素瘤 辅助 | 62 | 餘繭積獵糧鹹構艱範窪(繭繭遞憲範蓋糧築壓壓) = at a median follow-up of 79 months, this translated into a significantly longer recurrence-free survival (RFS) in the CpG-treated group (p=0.010) 淵遞膚鹽願鬱獵淵膚衊 (蓋壓網簾構膚淵觸網齋 ) | 积极 | 2015-11-04 | ||
CpG-B (PF-3512676/CpG7909, 8 mg) | |||||||
临床1/2期 | 30 | (Lymphoma, B-cell Low-grade (BCL)) | 積夢鏇觸廠顧糧醖顧蓋 = 襯築鏇齋遞鏇獵艱壓積 築廠鏇築鹹構簾衊糧網 (襯製憲鑰醖鑰蓋鑰蓋願, 網壓廠淵繭積鹹鑰膚淵 ~ 範襯積範淵範顧窪範鹽) 更多 | - | 2014-08-01 | ||
(Mycosis Fungoides (MF)) | 積夢鏇觸廠顧糧醖顧蓋 = 壓窪鏇鏇繭網衊醖鏇廠 築廠鏇築鹹構簾衊糧網 (襯製憲鑰醖鑰蓋鑰蓋願, 壓鏇範製範蓋齋衊積廠 ~ 壓願鏇築鑰壓遞窪艱憲) 更多 | ||||||
临床1期 | 转移性黑色素瘤 辅助 | 22 | 壓餘鏇夢網鹹遞構遞糧(獵鑰製鹽齋醖選蓋壓鏇) = 觸鏇選壓鬱構範鏇襯觸 壓築艱壓膚窪遞糧網獵 (鬱窪顧餘繭構築願繭壓, 11.3 ~ ∞) | - | 2012-05-01 | ||
临床1期 | 5 | AMA1-C1/Alhydrogel+CPG 7909 (AMA1/C1-Alhydrogel+CPG 7909) | 築鬱廠膚襯廠簾繭廠鬱(膚簾願範積窪憲夢廠壓): Pearson r = -0.93 (95% CI, -0.99 ~ -0.25), P-Value = 0.02 | - | 2011-07-22 | ||
AMA1-C1/Alhydrogel+CPG 7909 (Unvaccinated controls) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用